Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,257,071 for its innovative catheter-based platform technology. The patent covers advanced systems combining nerve mapping and radiofrequency (RF) ablation technologies for treating nerve-related conditions. Key features include deployable microfingers with embedded sensors, real-time physiological monitoring, and adaptive modulation capabilities.
The technology utilizes a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity compared to existing solutions. The company's portfolio now includes over 80 issued patents and 40 pending applications. Autonomix plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for treating pancreatic cancer pain.
Autonomix Medical (NASDAQ: AMIX) ha ottenuto il brevetto statunitense n. 12.257.071 per la sua innovativa piattaforma tecnologica basata su cateteri. Il brevetto copre sistemi avanzati che combinano mappatura nervosa e tecnologie di ablazione a radiofrequenza (RF) per il trattamento di condizioni legate ai nervi. Le caratteristiche principali includono microdita dispiegabili con sensori integrati, monitoraggio fisiologico in tempo reale e capacità di modulazione adattativa.
La tecnologia utilizza un array di antenne con microchip sensoriale basato su catetere in grado di rilevare e differenziare segnali neurali con una sensibilità superiore rispetto alle soluzioni esistenti. Il portafoglio brevetti dell'azienda comprende ora oltre 80 brevetti concessi e 40 domande in attesa. Autonomix prevede di presentare una richiesta di Esenzione per Dispositivo Sperimentale (IDE) e di avviare studi clinici negli Stati Uniti nel 2025 per il trattamento del dolore da cancro al pancreas.
Autonomix Medical (NASDAQ: AMIX) ha recibido la patente estadounidense No. 12,257,071 para su innovadora plataforma tecnológica basada en catéteres. La patente cubre sistemas avanzados que combinan mapeo nervioso y tecnologías de ablación por radiofrecuencia (RF) para tratar condiciones relacionadas con los nervios. Las características clave incluyen microdedos desplegables con sensores integrados, monitoreo fisiológico en tiempo real y capacidades de modulación adaptativa.
La tecnología utiliza una matriz de antenas con microchip sensor basado en catéter que puede detectar y diferenciar señales neuronales con mayor sensibilidad en comparación con las soluciones actuales. La cartera de la compañía ahora incluye más de 80 patentes concedidas y 40 solicitudes pendientes. Autonomix planea presentar una Exención para Dispositivo de Investigación (IDE) y comenzar ensayos clínicos en EE. UU. en 2025 para tratar el dolor del cáncer de páncreas.
Autonomix Medical (NASDAQ: AMIX)가 혁신적인 카테터 기반 플랫폼 기술에 대해 미국 특허 번호 12,257,071을 획득했습니다. 이 특허는 신경 맵핑 및 고주파(RF) 절제 기술을 결합한 첨단 시스템을 포함하며, 신경 관련 질환 치료에 적용됩니다. 주요 특징으로는 내장 센서가 탑재된 배치 가능한 마이크로핑거, 실시간 생리학적 모니터링, 적응형 조절 기능이 있습니다.
이 기술은 기존 솔루션보다 향상된 감도로 신경 신호를 감지하고 구분할 수 있는 카테터 기반 마이크로칩 센서 배열 안테나를 활용합니다. 회사의 특허 포트폴리오는 현재 80건 이상의 등록 특허와 40건의 출원 중인 특허를 포함하고 있습니다. Autonomix는 2025년에 췌장암 통증 치료를 위한 미국 임상시험 시작을 위해 임상시험용 기기 면제(IDE)를 제출할 계획입니다.
Autonomix Medical (NASDAQ : AMIX) s’est vu accorder le brevet américain n° 12 257 071 pour sa technologie innovante de plateforme basée sur un cathéter. Le brevet couvre des systèmes avancés combinant cartographie nerveuse et technologies d’ablation par radiofréquence (RF) pour traiter les affections liées aux nerfs. Les caractéristiques clés incluent des microdoigts déployables avec capteurs intégrés, une surveillance physiologique en temps réel et des capacités de modulation adaptative.
La technologie utilise un réseau d’antennes à micro-puces basé sur cathéter capable de détecter et différencier les signaux neuronaux avec une sensibilité améliorée par rapport aux solutions existantes. Le portefeuille de brevets de l’entreprise comprend désormais plus de 80 brevets délivrés et 40 demandes en cours. Autonomix prévoit de soumettre une demande d’exemption pour dispositif expérimental (IDE) et de débuter des essais cliniques aux États-Unis en 2025 pour traiter la douleur liée au cancer du pancréas.
Autonomix Medical (NASDAQ: AMIX) wurde das US-Patent Nr. 12.257.071 für seine innovative katheterbasierte Plattformtechnologie erteilt. Das Patent umfasst fortschrittliche Systeme, die Nerven-Mapping und Radiofrequenz-(RF)-Ablationstechnologien zur Behandlung von nervenbezogenen Erkrankungen kombinieren. Zu den Hauptmerkmalen gehören ausfahrbare Mikro-Finger mit integrierten Sensoren, Echtzeit-physiologische Überwachung und adaptive Modulationsfähigkeiten.
Die Technologie nutzt eine katheterbasierte Mikrochip-Sensorelement-Antenne, die neuronale Signale mit verbesserter Empfindlichkeit im Vergleich zu bestehenden Lösungen erkennen und unterscheiden kann. Das Patentportfolio des Unternehmens umfasst nun über 80 erteilte Patente und 40 anhängige Anmeldungen. Autonomix plant, 2025 eine Investigational Device Exemption (IDE) einzureichen und klinische Studien in den USA zur Behandlung von Bauchspeicheldrüsenkrebs-Schmerzen zu beginnen.
- None.
- Product still in pre-clinical phase, pending IDE submission
- Clinical trials haven't started yet, indicating long path to commercialization
- Potential regulatory hurdles ahead with FDA approval process
Insights
Autonomix secures strategic patent fortifying their position in precision nerve treatment, bolstering commercial pathway ahead of 2025 clinical trials.
This newly granted patent (No. 12,257,071) significantly strengthens Autonomix's competitive position in the neurovascular medical device space. The patent specifically covers a sophisticated catheter-based system that integrates both nerve mapping and radiofrequency ablation capabilities—a technical combination that enables highly precise targeting of overactive nerves through minimally invasive procedures.
The technology's key protected features include deployable microfingers with embedded sensors, real-time physiological monitoring capabilities, and an integrated system that can map, stimulate, ablate, and assess nerve activity. More importantly, the patent covers feedback-driven control systems that support adaptive modulation of therapeutic output based on multiple physiological inputs.
This intellectual property acquisition represents a critical strategic asset as Autonomix prepares for its 2025 Investigational Device Exemption (IDE) submission and clinical trials for pancreatic cancer pain treatment. The patent fits perfectly within their broader portfolio of 80 issued patents and 40 pending applications, creating significant barriers to entry for potential competitors.
From a technological differentiation standpoint, Autonomix's platform stands out through its microchip sensing array antenna that reportedly offers superior neural signal detection compared to existing technologies. This sense-treat-verify approach addresses a major gap in precision nerve treatment that could potentially disrupt multiple high-value markets including chronic pain management, hypertension, and cardiology applications.
Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics
Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications
THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,257,071 (‘071 patent) titled Controlled sympathectomy and micro-ablation systems and methods. The newly issued ‘071 patent relates to, but is not necessarily limited to, advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, providing enhanced precision in treating nerve-related conditions. These systems allow for the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. The granted patent represents a significant step forward in Autonomix’s mission to improve patient outcomes by delivering more effective, less invasive treatments for neurological conditions such as chronic pain, hypertension and a myriad of other nerve-related disorders.
“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances our intellectual property position in the rapidly growing nerve-focused therapeutics space, allowing us to protect our offerings and deliver improved solutions for both clinicians and patients. This patent is a vital addition to our expanding portfolio as we continue working toward our goal of revolutionizing the treatment of nerve-related conditions,” commented Brad Hauser, CEO of Autonomix.
In particular, the ‘071 patent covers key features of the technology including, but not necessarily limited to: Deployable microfingers with embedded sensors for real-time physiological monitoring; Ability to map, stimulate, ablate, and assess nerve activity in a single integrated system; Feedback-driven control of multiple types of procedures such as RF ablation, ultrasound, or chemical delivery; and Supports adaptive modulation to adjust therapeutic output in real-time based on inputs like EMG, MMG, and bioimpedance. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.
Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.
The Company expects to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, and timing of its submission of an IDE and the commencement of U.S. clinical trials. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What is the significance of Autonomix Medical's (AMIX) new patent?
What medical conditions can Autonomix Medical's (AMIX) technology treat?
When will Autonomix Medical (AMIX) begin clinical trials?
How many patents does Autonomix Medical (AMIX) currently hold?
What advantages does Autonomix Medical's (AMIX) technology offer over current treatments?
